Zyprexa At "Halftime": Lilly Remains Committed To Antipsychotic
This article was originally published in The Pink Sheet Daily
Executive Summary
Lilly's 2005 marketing strategy aims to stem declining sales for the atypical antipsychotic Zyprexa, Exec. VP-Pharmaceutical Operation John Lechleiter, PhD, said